Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 10/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12601821 | 0.92 | GRM5 (0.71) | GRM5CYP3A4DRD3SLC6A3MEN1 | |
| SCHEMBL1979922 | 0.83 | GRM5 (1.00) | GRM5CYP3A4DRD3SLC6A3MEN1 | |
| SCHEMBL6918521 | 0.80 | GRM5 (0.70) | GRM5CYP3A4DRD3SLC6A3 | |
| SCHEMBL6919031 | 0.80 | GRM5 (0.69) | GRM5CYP3A4DRD3SLC6A3MEN1 | |
| SCHEMBL6918537 | 0.77 | GRM5 (0.62) | GRM5CYP3A4DRD3SLC6A3 | |
| SCHEMBL6918849 | 0.77 | GRM5 (0.65) | GRM5CYP3A4DRD3SLC6A3 | |
| SCHEMBL6918588 | 0.76 | GRM5 (0.67) | GRM5NPC1RAB9AKMT2A | |
| SCHEMBL6918313 | 0.75 | GRM5 (0.60) | GRM5CYP3A4 | |
| SCHEMBL6918192 | 0.74 | GRM5 (0.59) | GRM5MEN1NPC1RAB9AKMT2A | |
| SCHEMBL6918291 | 0.74 | GRM5 (0.60) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796295-B2 | Substituted benzamide analogs as mGluR5 negative allosteric modulators and methods of making and using the same | VANDERBILT UNIVERSITY (US) | 2014-08-05 | — | — | US | disclosed |
| US-20110152299-A1 | SUBSTITUTED BENZAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-06-23 | — | — | US | disclosed |
| WO-2011035209-A1 | SUBSTITUTED BENZAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | VANDERBILT UNIVERSTIY (US) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152299-A1 | SUBSTITUTED BENZAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | GRM5, GRIK5, GRIN2A | GRM5 1/4885CYP3A4 3527/4885DRD3 412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.